TRIB — Trinity Biotech Income Statement
0.000.00%
Last trade - 00:00
- $2.80m
- $53.97m
- $56.83m
- 30
- 68
- 31
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 6-K | 6-K |
Standards: | IFRS | IFRS | IFRS | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 90.4 | 102 | 93 | 62.5 | 56.8 |
Cost of Revenue | |||||
Gross Profit | 38.1 | 48.6 | 38.1 | 17.3 | 19.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 115 | 102 | 86.3 | 81.9 | 83.9 |
Operating Profit | -24.1 | 0.082 | 6.63 | -19.3 | -27 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -30 | -6.63 | 0.751 | -43.8 | -36.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -29 | -6.01 | 0.929 | -43.6 | -36.9 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -28.9 | -6.39 | 0.875 | -41 | -24 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.9 | -6.39 | 0.875 | -41 | -24 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.789 | 0.261 | 0.144 | -0.295 | -0.194 |